<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The aim of the present study was to assess the efficacy of <z:chebi fb="0" ids="28445">vincristine</z:chebi>-laden platelet transfusion for patients with refractory <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Twenty evaluable patients who received <z:chebi fb="0" ids="28445">vincristine</z:chebi>-laden platelets for refractory <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> were included in this retrospective study </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="28445">Vincristine</z:chebi> (1 mg) was added to the platelets and incubated for one hour prior to transfusion </plain></SENT>
<SENT sid="3" pm="."><plain>Serial platelet counts following <z:chebi fb="0" ids="28445">vincristine</z:chebi>-laden platelet transfusion and units of platelets transfused in the week prior to and the week after transfusion of <z:chebi fb="0" ids="28445">vincristine</z:chebi>-laden platelets were evaluated </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The underlying diseases of the patients were <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> (n =4), <z:hpo ids='HP_0003002'>breast cancer</z:hpo> following autologous hematopoietic stem cell transplantation and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (n=3 each), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n=2), <z:hpo ids='HP_0006721'>acute lymphoid leukemia</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005526'>lymphoid leukemia</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e>, <z:e sem="disease" ids="C0004030" disease_type="Disease or Syndrome" abbrv="">aspergillosis</z:e>, <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">cytomegalovirus infection</z:e> and <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (n = 1 each) </plain></SENT>
<SENT sid="5" pm="."><plain>The median rate of change of platelet count after transfusion of <z:chebi fb="0" ids="28445">vincristine</z:chebi>-laden platelets was 550/microL/day (range, -1,000 to 12,8001/microL/day; p=0.003) </plain></SENT>
<SENT sid="6" pm="."><plain>The median change in the number of units of platelets transfused in the week following <z:chebi fb="0" ids="28445">vincristine</z:chebi>-laden platelet transfusion was -1.5 as compared to the week prior to the transfusion (p=0.031) </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with a primary marrow disorder exhibited no difference in either the rate of change in platelet count or in the difference in the units of platelets transfused compared to those without a primary <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">bone marrow disorder</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="28445">Vincristine</z:chebi>-laden platelet transfusion was associated with significantly <z:hpo ids='HP_0001894'>increased platelet counts</z:hpo> and a subsequent decrease in platelet transfusion </plain></SENT>
</text></document>